Researchers have reported positive results from a large clinical trial testing a new personalized cancer vaccine used in combination with an established immunotherapy medication. The trial involved 1,137 adults with melanoma who had undergone surgical removal of their tumors. Approximately two-thirds of participants received the experimental vaccine alongside Keytruda, an immunotherapy drug that helps the immune system identify and attack cancer cells, while the remaining participants received a placebo alongside the same immunotherapy.
The vaccine, named Intismeran, employs messenger RNA technology similar to some COVID-19 vaccines. What distinguishes this approach is its personalization—each vaccine is tailored to individual patients using genetic information from their own tumors to train the immune system to recognize and target cancer cells if they return. After two years of follow-up, patients who received the vaccine experienced significantly reduced rates of melanoma recurrence and metastasis compared to those receiving immunotherapy alone, with a 42% reduction in the risk of death or disease recurrence and a 38% reduction in melanoma spread.
The pharmaceutical companies MSD and Moderna, which developed the vaccine, have indicated they are exploring the same approach for other cancer types, including kidney, bladder, and lung cancers. Both companies stated they are engaging with regulatory authorities with the possibility of seeking approval as soon as next year. However, independent cancer specialists emphasized that while the results are noteworthy, longer-term follow-up studies remain necessary to confirm whether the treatment genuinely improves overall survival rates for most patients.
The trial will continue to monitor participants for cancer recurrence and to assess long-term survival outcomes. Experts also noted that broader adoption within healthcare systems will depend on cost considerations, as the approach requires individual tumor genetic analysis and personalized vaccine manufacturing for each patient. The complete trial findings are scheduled for presentation at a major European oncology conference, though the results have not yet undergone peer-review publication in a medical journal.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI